CTI Life Sciences
Founded in Montreal, Canada in 2006, CTI Life Sciences is a venture capital firm focusing on investments in the life sciences sector. It primarily invests in biotechnology, medical technology, and pharmaceutical companies at the pre-clinical to proof-of-concept stages, with a secondary focus on proof-of-concept to Phase III stages. The firm prefers investments in North America, particularly the United States and Canada.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Nova Scotia
IMV
Post in 2016
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.